Older Patients with Stage 1 Thyroid Cancer Paradoxically Show Better Survival

Share this content:

the Cancer Therapy Advisor take:

Older patients with stage 1 differentiated thyroid cancer (DTC) paradoxically show better survival than expected based on age and sex, according to a German study published in the Journal of Nuclear Medicine.

Researchers from the University Hospital Münster analyzed 2,428 patients with DTC who underwent treatment from 1965 to 2013 in order to compare overall survival with the general population. Subgroup analysis was also performed in regard to age at diagnosis, with overall survival compared with expected survival in the general population.

The researchers found that overall survival of patients with stage 1 disease was paradoxically better in patients with DTC compared with expected survival. Upon subgroup analysis, they found a significantly lower mortality rate in elderly patients aged 60 or older with stage 1 disease.

However, patients who were between the ages of 20 to 45 who had distant metastases at diagnosis had a significantly increased mortality rate, and other patients with stage 2 disease had normal mortality.

“For all other DTC patients regardless of age or TNM stage, no significant survival difference was seen,” the authors concluded.

Older Patients with Stage 1 Thyroid Cancer Paradoxically Show Better Survival
Older patients with stage 1 DTC paradoxically show better survival than expected based on age and sex.
The aim of this study was to compare the overall survival of a large, single-center cohort of patients who had differentiated thyroid cancer (DTC) with that of a matched general population.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters